WoodTrust Financial Corp Sells 2,000 Shares of Bristol-Myers Squibb (NYSE:BMY)

WoodTrust Financial Corp reduced its position in shares of Bristol-Myers Squibb (NYSE:BMYFree Report) by 16.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,917 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the quarter. WoodTrust Financial Corp’s holdings in Bristol-Myers Squibb were worth $508,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. Norges Bank bought a new stake in Bristol-Myers Squibb during the 4th quarter worth about $1,873,696,000. Moneta Group Investment Advisors LLC raised its holdings in Bristol-Myers Squibb by 114,228.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 21,469,785 shares of the biopharmaceutical company’s stock worth $1,544,751,000 after purchasing an additional 21,451,006 shares during the last quarter. Pacer Advisors Inc. raised its holdings in Bristol-Myers Squibb by 48.0% during the 4th quarter. Pacer Advisors Inc. now owns 7,830,948 shares of the biopharmaceutical company’s stock worth $401,806,000 after purchasing an additional 2,540,360 shares during the last quarter. AustralianSuper Pty Ltd bought a new stake in Bristol-Myers Squibb during the 4th quarter worth about $86,965,000. Finally, Cowa LLC raised its holdings in Bristol-Myers Squibb by 9,777.8% during the 1st quarter. Cowa LLC now owns 1,657,894 shares of the biopharmaceutical company’s stock worth $1,211,000 after purchasing an additional 1,641,110 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BMY has been the subject of several analyst reports. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $68.00 to $60.00 in a research report on Wednesday, January 3rd. Finally, Wells Fargo & Company decreased their target price on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $61.12.

View Our Latest Stock Report on Bristol-Myers Squibb

Bristol-Myers Squibb Stock Down 0.8 %

NYSE BMY traded down $0.42 during trading on Wednesday, hitting $52.32. The stock had a trading volume of 5,276,559 shares, compared to its average volume of 16,471,133. The company has a market capitalization of $106.04 billion, a PE ratio of 13.67, a P/E/G ratio of 1.60 and a beta of 0.39. The company’s 50-day moving average price is $51.08 and its two-hundred day moving average price is $52.21. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. Bristol-Myers Squibb has a 12 month low of $47.58 and a 12 month high of $71.07.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.55 by $0.15. The firm had revenue of $11.48 billion for the quarter, compared to analysts’ expectations of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.82 EPS. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 6.61 EPS for the current year.

Bristol-Myers Squibb announced that its Board of Directors has initiated a share repurchase program on Thursday, December 7th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to reacquire up to 2.9% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.59%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 62.18%.

Bristol-Myers Squibb Company Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Further Reading

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.